Guerbet | Jotup

Guerbet Announces Appointment of Jared Houk as Commercial Vice President for North America

Retrieved on:

Wednesday, January 12, 2022

Patient, Commercial, COVID-19, Agent handling, Growth, Solution, Canadian American Business Council, Leadership, Development, AGFA, Research and development, Multimedia, AI, Senior, Pharmaceutical industry, Guerbet

PRINCETON, N.J., Jan. 12, 2022 /PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, announced today that Jared Houk has been appointed Commercial Vice President, North America.

Key Points:

PRINCETON, N.J., Jan. 12, 2022 /PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, announced today that Jared Houk has been appointed Commercial Vice President, North America.
In this role, Houk will oversee and ensure the growth of Guerbet diagnostic and interventional solutions together with the digital and AI portfolio.
Prior to joining Guerbet, Houkserved as Senior Vice President and North American Business Leader at AGFA where he launched and managed the Radiology Solutions division in North America, driving revenue gains across various economic climates and challenges, including significant growth during the COVID-19 pandemic.
"It's a very exciting time to join imaging leader Guerbet in their continued pursuit of excellence for patients and providers.

Guerbet: 2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category

Retrieved on:

Tuesday, January 4, 2022

In 2021, Guerbet obtained a B rating for its 2020 information and data.

Key Points:

In 2021, Guerbet obtained a B rating for its 2020 information and data.
This result reflects our awareness of 2020 climate issues but does not yet reflect the climate strategy and decarbonization objectives currently under development.
**Since 1980, Helpvia has been a leader in referencing, purchasing, and consulting for healthcare institutions.
Helpvias CSR policy supports healthcare institutions in their approach to the three economic, social and environmentally sustainable development challenges.

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Retrieved on:

Tuesday, December 14, 2021

MILAN, Italy, Dec. 14, 2021 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, and Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, today announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent. This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names. The companies will also collaborate on manufacturing, as well as research and development for future indications. Financial terms of the transaction are not disclosed.

Key Points:

This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names.
Both Guerbet and Bracco Imaging each own valuable intellectual property relating to Gadopiclenol.
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.
Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine.

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Retrieved on:

Tuesday, December 14, 2021

MILAN, Italy, Dec. 14, 2021 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, and Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, today announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent. This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names. The companies will also collaborate on manufacturing, as well as research and development for future indications. Financial terms of the transaction are not disclosed.

Key Points:

This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names.
Both Guerbet and Bracco Imaging each own valuable intellectual property relating to Gadopiclenol.
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.
Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine.

Guerbet: Revenue at June 30, 2021

Retrieved on:

Thursday, July 22, 2021

Finance, Money, Profit, Fundamental analysis, Economy, Income statement, Guerbet, Earnings before interest and taxes, Earnings before interest, taxes, depreciation and amortization, Depreciation, Amortization, Euronext

X-ray revenue at constant exchange rates increased by 6.2%, based in particular on the good performance of Optiray during Q2 2021.

Key Points:

X-ray revenue at constant exchange rates increased by 6.2%, based in particular on the good performance of Optiray during Q2 2021.
Driven by the excellent sales momentum observed across all products in Q2, the Group is confident in its ability to maintain this pace of development.
Guerbet (GBT) is listed on Euronext Paris (segment Bmid caps) and generated 712 million in revenue in 2020.
First-half reported revenue totaled 196.0 million
4EBITDA: Operating income + net amortization, depreciation, and provisions.

Guerbet: Q1 2021 revenue

Retrieved on:

Thursday, April 22, 2021

Fundamental analysis, Profit, Finance, Earnings before interest, taxes, depreciation and amortization, Private equity, Euronext, Guerbet, Earnings before interest and taxes, Economy

b'Diagnostic Imaging sales were down 5.4% at CER, illustrating a gradual improvement compared with the decrease reported in Q4 2020.

Key Points:

b'Diagnostic Imaging sales were down 5.4% at CER, illustrating a gradual improvement compared with the decrease reported in Q4 2020.
At CER, revenue increased 19.0% to \xe2\x82\xac22.9 million.\nIn an uncertain environment, the Group remains confident that revenue growth will return in 2021 starting in Q2.\nIn terms of operational profitability, the Group is targeting the following EBITDA4 trends:\nIn the short term, a growing EBITDA in 2021, with a minimum rate EBITDA/Sales at least equal to the 2020 fiscal year rate (14.1%),\nIn the medium term, an improving EBITDA/Sales rate to ensure strong, lasting growth for the Group.\nAt Guerbet, we build lasting relationships so that we enable people to live better.
Guerbet (GBT) is listed on Euronext Paris (segment B\xe2\x80\x89\xe2\x80\x93\xe2\x80\x89mid caps) and generated \xe2\x82\xac712\xc2\xa0million in revenue in 2020.
For more information, please visit www.guerbet.com .\nCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements.

Guerbet: Additional information related to 2021 financial outlook

Retrieved on:

Monday, March 29, 2021

Guerbet, Euronext, VILLEPINTE

Villepinte, March 29, 2021 Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is detailing information related to 2021 outlook disclosed in the March 24th, 2021 press release entitled 2020 Annual Results.

Key Points:

Villepinte, March 29, 2021 Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is detailing information related to 2021 outlook disclosed in the March 24th, 2021 press release entitled 2020 Annual Results.
Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 712million in revenue in 2020.
Certain information contained in this press release does not reflect historical data but constitutes forward-looking statements.
For more information about Guerbet, please visit www.guerbet.com

Guerbet: 2020 annual results

Retrieved on:

Wednesday, March 24, 2021

Guerbet, Euronext, Earnings before interest, taxes, depreciation and amortization, Finance, Manufacturing, Economy

As of December 31, 2020, the Groups EBITDA remained above 100 million, representing a margin of 14.1% compared with 13.7% in 2019.

Key Points:

As of December 31, 2020, the Groups EBITDA remained above 100 million, representing a margin of 14.1% compared with 13.7% in 2019.
Over the 2020 financial year, the decrease in structural costs was just under 30 million, plus 9 million in manufacturing cost improvements.
The industrial organization was optimized with the sale of the Montreal manufacturing plant on July 15, 2020.
Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 712million in revenue in 2020.

Guerbet: Revenue 2020

Retrieved on:

Thursday, February 11, 2021

Finance, Financial markets, Money, Earnings before interest, taxes, depreciation and amortization, Fundamental analysis, Private equity, Profit, Euronext, Guerbet, Exchange rate

In Asia, total revenue at constant exchange rates for the financial year increased +2.2% to 168.8million (+1.0% at current exchange rates).

Key Points:

In Asia, total revenue at constant exchange rates for the financial year increased +2.2% to 168.8million (+1.0% at current exchange rates).
Diagnostic Imaging revenue totaled 637.2million, compared with 719.4million at December 31, 2019, down 11.4% at constant exchange rates (-14.5% at 615.2million at current exchange rates).
The Group's projected EBITDA margin for the 2020 financial year is around 14% of revenue, thanks in particular to the strict management of structural costs, which should have a positive impact on profitability once activity returns to normal.
Guerbet (GBT) is listed on Euronext Paris (segment B mid caps) and generated 712million in revenue in 2020.

$997 Million Worldwide Guerbet Alcohols Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on:

Friday, January 15, 2021

Chemicals, Plastics, Manufacturing, Fatty alcohols, Guerbet reaction, Guerbet

The "Guerbet Alcohols - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Guerbet Alcohols - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
The 288-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
The U.S. Market is Estimated at $269.3 Million, While China is Forecast to Grow at 6.4% CAGR
The Guerbet Alcohols market in the U.S. is estimated at US$269.3 Million in the year 2020.
China, the world's second largest economy, is forecast to reach a projected market size of US$265.4 Million by the year 2027 trailing a CAGR of 6.3% over the analysis period 2020 to 2027.